Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Here To Stay: Inception Sciences Shows Why Build-To-Buy Works

This article was originally published in Start Up

Executive Summary

Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.

Advertisement

Related Content

VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
Spero Therapeutics: Remodeling Antibiotics
Versant Launches Inception IBD, A New Company With Old Roots
Versant Continues “Build-To-Buy” With New Fund
BMS' Purchase Of Amira: When An Acquisition Is Really An Asset Sale

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel